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Purpose: In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does
not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be
treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear.
Methods and Materials: In this work, we suggest shifting this qualitative null hypothesis and describe a mathematical model
that can be used to frame a new, quantitative null. We begin with a very simple formulation of tumor growth, an exponential
function, and illustrate how the same intervention (removing a given number of cells from the tumor) at different times affects
survival. Additionally, we postulate where recent clinical trials fit into this parameter space and discuss the implications of
clinical trial design in changing these quantitative parameters.
Results: Our model shows that although any amount of cell kill will extend survival, in many cases the extent is so small as to
be unnoticeable in a clinical context or is outweighed by factors related to toxicity and treatment time.
Conclusions: Recasting the null in these quantitative terms will allow trialists to design trials specifically to increase understanding of the circumstances (patient selection, disease burden, tumor growth kinetics) that can lead to improved overall
survival when targeting metastatic lesions, rather than whether targeting metastases extends survival for patients with (oligo-) metastatic disease. Ó 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
In the treatment of patients with metastatic cancer, the
current paradigm states that targeted treatment of metastatic
lesions does not prolong life. This paradigm forms the basis
of clinical trial null hypotheses, where trials are built to test
the null hypothesis that patients garner no overall survival
(OS) benefit from targeting metastatic lesions.
The development of distant metastases is the forerunner
of cancer-related death.1-3 A hallmark of cancer, the
dissemination of cancer cells from their origin to distant
sites results from a complex cascade of biological events,
which may subsequently allow for even more efficient
tumor propagation.4-6 Eradicating as much metastatic disease as feasibly possible to halt said process is a natural
inclination. Yet, historically, a guiding principle in treating
cancer has been that targeting metastatic lesions leads to
poor outcomes because the treatment is either too late or
too morbid. However, with advancing imaging technology
and increasingly precise techniques for targeting lesions, a
much larger proportion of metastatic disease can be
treated.7 As a result, the life-extending benefit of targeting
metastatic disease is becoming increasingly clear.
Metastatic stage is typically described as a binary variable in a clinical setting, either present or not (M0 or M1),
although certain cancer subtypes (e.g. colon, prostate) now
have more gradiation in classifying a patient’s metastatic
stage.8 The term “oligometastatic state” was first described
in 1995 as an intermediary between localized and widespread metastatic disease where metastasis-directed treatment has the potential to be curative.9 Since then, results
from several exploratory studies and randomized controlled
trials using metastasis-directed therapy in such patients
have accumulated to support its existence.10,11
Consensus definitions have since been proposed to
further refine subgroups of oligometastasis.12-14 For
example, oligometastatic disease at presentation and the
development of oligometastatic disease after definitive
treatment of nonmetastatic cancer have been designated
“synchronous oligometastases” and “metachronous oligorecurrence,” respectively. “Oligoprogression” describes
growth of few metastases in the setting of otherwise stable
(or responsive) disease while undergoing systemic therapy,
and “oligopersistence” is characterized by having several
lesions that have a poorer response to systemic therapy than
others. Intrapatient heterogeneity often complicates
diagnostics even further, where some lesions respond to
therapeutics while others persist. These designations (and
many more not listed) underscore the complexity with
which researchers and clinicians are coming to understand
this disease state.
In addition to refining the term “oligometastatic,” clinicians have examined the benefit of treating patients with
oligometastasis.15,16 The implicit null hypothesis of these
investigations, that targeting metastatic disease does not
provide a life-extending benefit, stems from the current
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paradigm of metastatic cancer treatment. Table 1 summarizes the results of some of these recent phase 2 and 3
clinical trials, demonstrating that this null hypothesis is
frequently (but not always) refuted. Even accounting for
known positive publication bias,17,18 substantial evidence
supports a changing paradigm in the treatment of oligometastatic patients. However, despite many studies showing
a significant increase in OS when metastatic lesions are
targeted, the null hypothesis in ongoing clinical trial planning has not changed.
In this work, we suggest shifting this qualitative null
hypothesis and describe a mathematical model that can be
used to frame a new, quantitative null. We begin with a very
simple formulation of tumor growth, an exponential function, and use it to show that although any amount of cell kill
will extend survival, in many cases the extent is so small as
to be unnoticeable in a clinical context or out-weighed by
factors related to toxicity and treatment time. Recasting the
null in these quantitative terms will allow trialists to design
trials specifically to increase understanding of what circumstances (patient selection, disease burden, tumor
growth kinetics) can lead to improved OS when targeting
metastatic lesions, rather than determining whether targeting metastases can extend survival for patients with (oligo-)
metastatic disease. We purposely began with the most
simplistic possible mathematical model, considering only
total disease burden and doubling time. We did not consider
complexities such as space, metastatic locations/connectedness,19 immune interactions, or any heterogeneitiesdall
things that could be considered in future iterations, but
which make the model less generalizable. Finally, a sensitivity analysis was performed to confirm that our findings
were consistent using alternative ordinary differential
equations (ODEs) that may be used to model tumor
growth.20
Because of its breadth, the current qualitative null hypothesis may be incorrectly accepted or rejected without a
quantitative model to help design optimal patient and
treatment parameters. Numerous qualitative and quantitative prognostic factors exist to help identify patients with
metastatic disease that is likely to follow a relatively
indolent course. For example, with slower disease progression, patients are more likely to derive greater benefit
from aggressively targeting metastases. Other characteristics include the number of lesions and organs involved, the
time course of presentation and progression, tumor histology, patient innate and adaptive immunity, and various
biological features.21 It is crucial that we parse which of
these patient characteristics can meaningfully affect treatment outcomes in the setting of oligometastasis. By
rethinking the null hypothesis of metastatic cancer treatment, research efforts can better serve our patients by
bringing a deeper understanding of how well treatment
works, for whom it works best, and when it is most efficacious, rather than continually testing the implicit null
hypothesis.
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A summary of clinical trials that examine the benefit of providing local treatment to patients with oligometastases
CT phase

Primary location

Results

30, 31

2

NSCLC

Positive for PFS and OS

42

2

NSCLC (EGFR/ALK
negative)

Positive for PFS

32, 43

2

Variety

Positive for OS

37

2

Prostate (hormone sensitive)

Positive for composite of
progression metrics

44

2

Prostate

Positive for ADT-free
survival

35, 45

2

CRC

Positive for OS

Description
In the Gomez et al trial,
treating oligometastasis
(3 nonprimary lesions)
demonstrated significant
improvement in PFS and
OS compared with
maintenance therapy alone.
In the trial by Iyengar et al,
targeting the primary
lesion with radiation
therapy and
oligometastasis with SBRT
followed by maintenance
chemotherapy provided
significantly improved PFS
compared with
maintenance
chemotherapy alone.
In the SABR-COMET trial,
treating all sites of
oligometastatic cancer
with SABR demonstrated
significantly improved OS
compared with standard
palliative treatment.
In the ORIOLE trial, treating
all sites of oligometastates
with SABR led to
improved outcomes
measured by 6-month rate
of progression (by PSA,
imaging, symptoms,
androgen-deprivation
therapy initiation, and
survival) when compared
with observation alone.
In the STOMP trial, in
patients with metachronous
oligometastasis, using
metastasis-directed therapy
(SBRT or surgery)
provided longer ADT-free
survival compared with
surveillance alone.
In the EORTC 40004 trial,
treating liver metastases
(<10, no extrahepatic
disease) with RFA,
systemic treatment, and
þ/e resection led to longterm OS improvement
compared with systemic
treatment alone.
(continued on next page)
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Table 1 (continued )
References

CT phase

Primary location

Results

Description
In the RTOG 0937 trial,
treating oligometastasis
with PCI and consolidative
radiation therapy to both
the chest and metastases
did not improve OS and
did delay progression,
compared with PCI alone.
In the HORRAD trial, in
patients with metastases to
the bone (any amount),
providing radiation therapy
to the prostate along with
ADT did not improve OS
and did improve time to
PSA progression,
compared with ADT alone.
Exploratory subgroup
analysis suggested patients
with 4 bone metastases
may benefit from prostate
radiation therapy.
In Arm H of the STAMPEDE
trial, radiation therapy to
the prostate did not
improve OS in unfiltered
cohort of patients,
compared with lifelong
ADT. However, in a
prespecified subgroup
analysis, significant OS
improvement was observed
among those with lower
metastatic burden.
In a trial by You et al, the
addition of locoregional
radiation therapy to the
primary lesion improved
OS and PFS compared
with chemotherapy alone
in patients with (oligo- and
poly-) metastatic
nasopharyngeal carcinoma.

39

2

ES-SCLC

Positive for PFS, negative for
OS

46

3

Prostate

Positive for PSA progression,
negative for OS

36

3

Prostate

Negative for OS in complete
group, positive for OS in
patients with lower
metastatic burden

47

3

Nasopharynx

Positive for PFS and OS

Abbreviations: ADT Z androgen deprivation therapy; ALK Z anaplastic lymphoma kinase; CRC Z colorectal cancer; CT Z clinical trial; EGFR Z
epidermal growth factor receptor; EORTC Z European Organisation for Research and Treatment of Cancer; ES-SCLC Z extensive-stage small cell lung
cancer; NSCLC Z non-small cell lung cancer; ORIOLE Z Observation vs Sterotactic Ablative Radiation for Oligometastatic Prostate Cancer; OS Z
overall survival; PCI Z prophylactic cranial irradiation; PFS Z progression-free survival; PSA Z prostate-specific antigen; RFA Z radiofrequency
ablation; RTOG Z Radiation Therapy Oncology Group; SABR-COMET Z Sterotactic Ablative Radiotherapy for the Comprehensive Treatment of
Oligometastases; SBRT Z stereotactic body radiation therapy; STAMPEDE Z Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy; STOMP Z Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence
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Methods and Materials

time (e.g. upon detection of a metastasis). The total tumor
burden at the time of this treatment is denoted as Nd and the
number of cells killed is denoted as Nc cells; note, this
requires 0  Nc  Nd .
To illustrate how the same intervention (removing Nc
cells from the tumor) at different times affects our measure
of survival, we plot several growth curves together in
Figure 1. The time when each of these curves reaches NT is
the time of death (td,x). The difference ðDtÞ between the
unperturbed time of death (td,1) and each subsequent
example intervention ðeg; Dt Ztd;2 td;1 Þ is the increase in
survival. We note that the earlier the intervention occurs
(smaller Nd), the greater the Dt and, therefore, increase in
survival. This is also true if we kill more cells (i.e. Nc
increases).
Although Figure 1 considers how a single intervention
will affect the “same” tumor, Figure E1 explores the effect
of altering tumor growth rate, r, on Dt after the same
intervention. This figure adds a faster tumor growth curve,
in addition to the curve seen in Figure 1. The same intervention (removal of Nc cells) occurs at the same time points
as the slower curve, yet the faster growing tumor
has a

smaller resulting change in survival time Dtf compared
with the slower growing tumor ðDts Þ.
Next, we will examine the analytical relationship between the change in survival ðDtÞ and the other parameters

Modeling tumor growth using an exponential
function
Beginning with a very simple model of tumor growth, an
exponential function, we explored the effect of treatment in
scenarios with different growth rates, treatment effectiveness,
and timing of the intervention. Although this overlooks many
of the realities of real human cancers, such as spatial, intra-,
and inter-tumoral22-24 heterogeneity, it captures many of the
essential aspects of growth.25 Furthermore, in the absence of
other specific knowledge, general arguments can be
expounded upon, but additional undetermined complexities
can severely limit generalizability. Let us then model a tumor
of size (cell number), N, beginning with a single cell, and a
growth rate, r, as follows:
NðtÞ Z ert
ð1Þ
A growth curve built using Equation 1 is displayed in
Figure 1 as a black line, denoted “Untreated.” The threshold
tumor burden (an arbitrary number of N Z 100 for illustrative purposes) that leads to patient death, NT, is represented by the horizontal black dashed line in Figure 1.
Next, we will assume that an intervention (e.g. stereotactic
body radiation therapy or metastasectomy) is given at some
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Treat early
Treat middle
Treat late
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110
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N
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80
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1100

1150

1200

N d3

NT
Untreated
Treat early
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0
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Fig. 1. Change in overall survival is modulated by when an oligometastasis-directed intervention occurs and the effectiveness of the intervention. We plotted an illustrative exponential growth curve from Equation 1 in black. At 3 different
times, we subtracted Nc cells from the curve to simulate an oligometastasis-directed intervention (orange markers), and the
tumor continued to grow at the original rate from the new size. These subsequent tumors then grew and eventually intersected
an arbitrary threshold cell (a surrogate for maximum tolerated disease burden) number (NT Z dashed horizontal line), and
there we could then determine the change in survival (vertical black lines, inset). The change in this time represents the Dt for
each intervention. n.b. These are not realistic parameters, but instead serve to illustrate the (qualitatively conserved) phenomenon. (A color version of this figure is available at https://doi.org/10.1016/j.ijrobp.2020.12.044).

376

International Journal of Radiation Oncology  Biology  Physics

Scarborough et al.

(r, Nc, Nd). This requires examining 2 tumor growth curves,
one with unperturbed growth starting at Nd and the other
with perturbed growth beginning at ðNd Nc Þ: In other
words, the perturbed curve will have the same growth
characteristics as the unperturbed curve, but it will have Nc
cells removed as “treatment.” Then we will calculate
the offset of time between the 2 curves when they reach
NT, (i.e. Dt).
Graphically, we are asking how large the difference on
the time axis is between where the treated and untreated
curves intersect with NT (the black dashed line), denoted by
colored circles in Figure 1 and Figure E1. Mathematically,
we find the difference between td,1 and td,2: Dt when
ðNd Þert1 Z ðNd  Nc Þert2 Z NT . This relation is


1
Nd
Dt Z ln
ð2Þ
r
ðNd  Nc Þ

(increasing Nc), and lower burden at time of treatment
(lower Nd) make for a larger survival benefit, as we have
intuited. Additionally, it is important to note that Dt is not
dependent on the threshold chosen for NT, where tumor
burden leads to death.
Given the intuitive nature of these results, one may
question the value of such a model. First, this model allows
for the quantitative exploration of what was previously an
exclusively qualitatively described phenomenon. This allows
for formal interrogation of the individual values of each
parameter, a crucial step in quantitative reasoning during
clinical trial design. In doing so, a framework for parameter
estimation can help trialists perform sensible power calculations. This would require measuring distributions of each
of these parameters, as it is clear that heterogeneity (and
uncertainty) exists in each. Furthermore, this would allow for
error propagation in addition to power calculations. With
recent work trying to incorporate toxicity into survival analyses in radiation oncology,26 we have the opportunity to

The observations from before are maintained: Slower
growing tumors (smaller r), more effective interventions

A

3000
2500
2000

N(t)

NT = 1500

Exponential

1500

Mendelsohn
Logistic

1000

Linear
Surface

500

Gompertz
Bertalanffy

0
0

20

40

60

80

100

time (days)

120

Δt
(days)
16

B
Exponential

14.83

9.65

6.42

Mendelsohn

10.23

7.03

5.07

Logistic

11.82

7.56

5.10

12

Linear

11.49

7.41

5.07

10

Surface

11.26

7.41

5.16

Gompertz

9.85

6.27

4.36

8.53

6.15

4.67

Treat Early

Treat Middle

Treat Late

Bertalanffy

14

8
6
4

Fig. 2. Across 7 ordinary differential equations (ODE) tumor growth models, earlier intervention creates a larger
improvement in overall survival (OS). Models were produced using the parameters denoted by Murphy et al,20 where the 7
models were fit to 14 timepoints of xenograft tumor growth data from Worschech et al.27 (A) A comparison of the 7 growth
curves with no interventions built with various ODE models. Individual plots for each model and 3 intervention time points
may be found in Figure E2. (B) A heatmap demonstrating the change in OS (Dt days) for the same intervention (Nc Z 100) at
3 different time points for each ODE model. Each heatmap entry is annotated with the exact change in OS for the given model
and intervention timing. Treat early, treat middle, and treat late denote the intervention occurring at 20, 35, and 50 days,
respectively.
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formally probe the balance between benefit and harm in this
setting. Most importantly, however, it will remove the
confusion created when we test a qualitative null that is
likely neither able to be rejected nor upheld given the
sensitivity to the noise inherent in clinical data.

benefit the earlier it is performed. Each model with untreated,
early, middle, and late interventions is individually plotted in
Figure E2B-H, and Figure E2A shows all untreated models
together for comparison. Although not all models have as
extreme a difference as seen in the exponential model, this
quantitative trend, which is the main thrust of this study,
remains consistent.

Sensitivity analysis with alternative tumor growth
models

Parameter sweep of exponential growth model

To assess the consistency of our findings, we examined the 7
ODE models used by Murphy et al,20 where they fit each
model using 14 time points from a naked mouse xenograft
experiment by Worschech et al.27 The models included in
this analysis are as follows: exponential, Mendelsohn, logistic, linear, surface, Gompertz, and Bertalanffy. Figure 2A
shows all 7 models (including the exponential model) built
using the parameters denoted by Murphy et al.20 Using these
models, Figure 2B denotes the Dt; or change in OS, between
the untreated growth curves and growth curves with the same
intervention at early, middle, and late timing. Here, we see
that all models show that the same intervention has a greater
OS benefit, td = 100 days

Figure 3 demonstrates a benefit of using a quantitative
model with a sensitivity analysis to help us better understand the areas of the (very simplified) parameter space, a
range of possible parameter values, where the greatest opportunities lie. Given that this is a simple exponential
relation, the change in survival is monotone (always up or
down) in each parameter. However, because the tumor
growth curves were nonlinear, we chose to plot the sensitivity analysis on a log-log plane to improve the visualization of changes in parameter values.
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Fig. 3. The benefit of oligometastasis-directed therapy depends monotonically on the amount of cells killed, the tumor
burden, and tumor doubling time. We plotted 4 orders of magnitude of both Nc and Nd on a log scale. The color represents the
predicted number of days of overall survival benefit for each combination of Nc and Nd Each of the 4 subplots represents a
different “intrinsic” biology, modeled by different tumor doubling times. A td of 100, 200, 300, and 400 days corresponds to a
growth rate, r, of 0.0069, 0.0035, 0.0023, and 0.0017, respectively. Contour lines are shown for ease of comparison. A selection of trials from Table 1 are represented by red circles based on estimations of Nd, Nc, r, and td for each trial.
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Because we do not currently have known values for
these parameters, exploring a large sweep of values can be
instructive. We consider a continuous range for Nc in
½0; Nd ; where Nc Z 0 represents no intervention and Nc Z
Nd represents a cure. In these cases, DtZ 0 and DtZ N;
respectively. In Figure 3, we consider 4 discrete examples
of values for r, as this parameter’s effect is monotone
(where a case with lower r always derives more benefit
from oligometastasis-directed therapy than a case with
higher r). It is also important to note that this parameter is
likely modifiable with cytotoxic or targeted chemotherapy,
something we do not consider here, but this would be a
straightforward extension. This example will consider
growth rates that correspond to tumor doubling times of
100, 200, 300, and 400 days. These could represent tumors
such as small cell lung cancer (SCLC) in the fast extreme
or prostate cancer in the slow extreme. Figure 3 shows this
analysis with isoclines in black to denote lines of equal
effect. These curves demonstrate that any increase in Nc
(more cell kill per intervention, “up” on the y-axis) and/or
decrease in Nd (earlier intervention, “down” on the x-axis)
increases the OS benefit. It is interesting to note that the
movements (ie, Nc up and Nd down) mirror the historical
trend: Improvements in detection of oligometastasis via
anatomic or functional imaging have slowly pushed Nd
lower over the years, and the ability to safely (using stereotactic body radiation therapy or minimally invasive
surgery with continually lowering toxicity) target larger and
larger lesions (increasing Nc) has increased. This “creep” of
these values is one reason why the need for a recasting of
the null hypothesis is becoming clear, and why the null was
historically of greater clinical utility.

slow-growing tumor type that is detected late. Using
Equation 2, we assume parameters that are congruent with
each clinical scenario and calculate the change in survival
time between the treated and untreated growth curves.
These Dt values are then converted into hazard ratios (HRs)
relative to each other, with the largest change in survival
time relating to the most extreme HR (0.50) and the
smallest change in survival time leading to the HR closest
to 1 (0.80). In Table 2, we see that as the HR approaches 1,
the predicted sample size requirements become unreasonable for any oncology treatment clinical trial. This HR may
occur in a trial with a fast-growing tumor type (eg, SCLC)
that has widespread metastatic disease.
As seen in McClatchy et al29 and Scott et al,26 a more
technical method of assessing these theoretical sample size
calculations would be to perform an in silico clinical trial.
One would assume distributions for each parameter of interest (eg, r, Nd), sample each “patient” in the trial from
these distributions, assess survival time for treated and
untreated groups, and calculate the HR between the 2
groups. Even with this theoretical approach, however,
additional measurements would be required to appropriately estimate the distributions of the model parameters.
Post-trial data publication could provide a wealth of information to estimate these parameters. For example, tumor
imaging both before and after treatment could assess Nd
and Nc, and serial tumor biopsies could be used to inform a
distribution for tumor growth rate. Without these data,
however, we believe that the simpler method of converting
Dt to HR, shown in Table 2, provides an easier-to-interpret
example of sample size calculations.

Clinical correlation
Sample size calculation informed by exponential
growth model
Finally, we performed theoretical sample size calculations
(using the sample size estimator from Wang and Ji28) in 4
clinical scenarios: a fast-growing tumor type that is detected early, a fast-growing tumor type that is detected late, a
slow-growing tumor type that is detected early, and a

To demonstrate how clinical trial design can explore the
parameter space of this tumor growth model, we will review some recent clinical trials, which are also listed in
Table 1. This discussion reviews illustrative examples and
is not an exhaustive list of all clinical trials that test the
benefit of targeting oligometastases. For many trials, we
will estimate where design falls in the parameter space of

Table 2 Theoretical sample size calculations demonstrate that as the change in OS decreases, the HR gets closer to 1, and a larger
sample size is predicted
Tumor parameters

Doubling time (d)

Growth rate (r)

Nd

Nc

Dt (d)

HR

Sample size

Fast-growing tumor, early detection
Fast-growing tumor, late detection
Slow-growing tumor, early detection
Slow-growing tumor, late detection

100
100
400
400

0.0069
0.0069
0.0017
0.0017

10E10
10E11
10E10
10E11

5E10
5E10
5E10
5E10

100.0
7.4
400.0
29.6

0.60
0.80
0.50
0.70

82
14698
34
322

Using equation 2, Dt, representing change in OS, was calculated for 4 clinical scenarios. This predicted change in OS is translated to an estimated HR
to perform a sample size calculation. The sample size calculations assumed a type I error (a) of 0.05, power ð1 bÞ of 0.80, equal size of treatment arms,
and a superiority margin of 0.20. Sample size was estimated using a resource by Wang and Ji28 (http://riskcalc.org:3838/samplesize/), which references
Schoenfeld et al,48,49 for the calculation of sample size in parallel randomized control trials for assessing superiority of a treatment using time-to-event.
Abbreviations: HR Z hazard ratio; OS Z overall survival.
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Figure 3 and discuss how trial design can test the effects of
altering 1 or more parameters (e.g. Nd Nc, or r).
In a phase 2 trial by Gomez et al,30 49 patients with
oligometastatic (3 metastases) non-small cell lung cancer
without progression after first-line systemic therapy were
randomized to either maintenance systemic therapy/surveillance or local consolidative therapy (LCT) to all sites of
residual disease via surgery or radiation therapy. After
interim analysis demonstrated a substantial progressive free
survival benefit with LCT, the trial was closed early and
allowed for crossover to the LCT arm.30 With additional
follow-up, and despite crossover, LCT was associated with
improved OS of 41.2 months versus 17.0 months.31 We
placed this trial in the top right subplot of Figure 3 due to
the relatively fast growth rate of non-small cell lung cancer,
minimal tumor burden (3 metastases), and large Nc using
radiation therapy or surgery.
The Stereotactic Ablative Radiotherapy for the
Comprehensive Treatment of Oligometastases (SABRCOMET) study was a screening phase 2 trial that randomized 99 patients with oligometastatic disease
(5 metastases) of various histologies with a controlled
primary site to standard palliative therapy with or without
SABR to all metastatic lesions. The primary endpoint was
OS, which was initially improved with the addition of
SABR from 28 months to 48 months.32 With additional
follow-up, results were even more substantial, with a
median OS of 50 months using SABR versus 28 months in
the control arm.33 Because this trial included tumors of
many histologies, we cannot place the positive results in a
single subplot of Figure 3, but doing so post hoc patient by
patient would be illustrative. The SABR-COMET trial also
used stratified randomization to ensure that strata of
patients with 1 to 3 metastases and 4 to 5 metastases were
balanced in treatment assignments. Stratified randomization
helps balance treatment arm assignments between patient
populations with known prognostic factors and can
reduce the risk of type I and II errors in trials with
smaller sample sizes (<400 patients).34 In relation to our
model, by creating strata of the number of metastases, the
SABR-COMET trial was balanced based on tumor burden
at the time of treatment (Nd). In the future, other trials may
consider stratifying based on tumor growth rate (either
inferred by tumor type or measured from serial tumor biopsies), the sensitivity of imaging techniques (Nd or Nc), or
the efficacy of 2 treatment types (Nc).
In the phase 2 European Organisation for Research and
Treatment of Cancer (EORTC) 40004 trial, 119 patients
with fewer than 10 unresectable colorectal liver metastases
and no extrahepatic disease were randomized to systemic
therapy with or without local therapy using radiofrequency ablation (RFA) (with or without resection).
Although the primary endpoint of 30 months OS benefit
was not met, longer follow-up led to improved OS with
RFA from 40.5 months to 45.6 months.35 With a relatively
slow-growing tumor subtype, a large Nd, and a moderate
OS benefit, we estimated this clinical trial to fall in the
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bottom left subplot of the model’s parameter space found
in Figure 3.
The largest study was Arm H of the Systemic Therapy in
Advancing or Metastatic Prostate Cancer: Evaluation of
Drug Efficacy (STAMPEDE) trial, which was a phase 3
trial of 2061 patients with metastatic prostate cancer randomized to androgen deprivation therapy with or without
definitive radiation therapy to the prostate. Prespecified
subgroup analysis demonstrated no benefit to the addition
of prostate radiation therapy among those with a high
metastatic burden, defined as either visceral metastases or
4 bone metastases with 1 outside of the vertebral bodies
or pelvis. However, in the group of 819 patients with a low
metastatic burden, radiation therapy to the prostate
improved 3-year OS from 73% to 81%.36 In relation to our
model, this is equivalent to assuming that the 2 groups
(high and low metastatic burden) have different Nd at the
time of treatment but experience the same Nc It should be
noted that unlike other trials discussed, local therapy was
delivered only to the primary site, not the metastatic sites,
suggesting a benefit to cytoreduction. The estimated
parameter space position of these 2 subgroups (high metastatic burden and low metastatic burden) is found in the
bottom right subplot of Figure 3.
In the Observation vs Stereotactic Ablative Radiation for
Oligometastatic Prostate Cancer (ORIOLE) trial, patients
with metachronous oligometastatic prostate cancer with 3
sites as detected by conventional imaging were randomized
to surveillance or SABR to all sites.37 The primary
endpoint was a composite of disease progression metrics at
6 months, which was improved with SABR at 19% versus
61% in the control arm. Interestingly, a subgroup of patients underwent advanced imaging with prostate-specific
membrane antigen (PSMA) positron emission tomography
(PET), which has demonstrated greater sensitivity in
detecting prostate cancer metastases (putatively lowering
Nd).38 Among those patients for whom all PSMA
PETeavid sites were treated, the 6-month progression rate
was just 5% compared with 38% in those with untreated
sites. This subgroup analysis further supports that advanced
imaging can better identify metastases, and treating all sites
improves outcomes. By using a more sensitive technology
in detecting (and therefore targeting) metastases, we see
that a greater Nc increases progression-free survival, even if
Nd remains the same. We estimate the parameter space for
this subgroup analysis in the bottom right subplot of
Figure 3.
Not all trials have demonstrated benefit to the addition
of metastasis-directed therapy. For example, Radiation
Therapy Oncology Group (RTOG) 0937 was a phase 2
study of 86 patients with extensive stage SCLC with at least
a partial response to chemotherapy and 1 to 4 extracranial
metastases who were randomized to prophylactic cranial
irradiation with or without consolidative radiation therapy
to the chest and all metastatic sites. The primary endpoint
of 1-year OS was not significantly different; 60% in the
control arm and 51% in the consolidative radiation
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therapy arm.39 This negative result is estimated to be in the
top left subplot of Figure 3, due to the rapid growth of
SCLC. Here, this model could have still been useful by
informing the sample size calculations (Table 2), given the
parameter estimates of the trial’s patient population.

Conclusions
In this work, we have used a simple exponential model of
tumor growth to demonstrate why recent improvements in
metastasis detection and treatment may allow us to reconsider the null hypothesis when treating patients with oligometastases. Specifically, more sensitive techniques to
localize metastases (as seen with PSMA imaging) increase
how many tumor cells are removed, Nc, when considering
patients at similar stages. When used for surveillance, these
imaging techniques can decrease the tumor burden at the
time of treatment, Nd, while still increasing the efficacy of
therapy, Nc, potentially leading to clinically significant
improved OS. Next, advancements in the ability to
administer local therapy to all sites of disease with surgical
resection, radiation therapy, and/or ablative procedures
such as RFA have allowed for more effective, precise
eradication of metastatic lesions with reduced associated
morbidity. Furthermore, novel immunotherapies, cytotoxic
chemotherapies, and other targeted therapies can likely
decrease the growth rate, r, of tumors.
A mathematical model provides the distinct advantage
of testing quantitative hypotheses to optimize the treatment
of patients with oligometastases. Parameter selection
regarding number of oligometastases, measurements of
tumor burden, and efficacy of treatment options can be
examined with robust hypotheses born from simulated
results. Additionally, with increased translation between the
bench and bedside, some model parameters (eg, r, tumor
growth rate) may be inferred using serial tumor biopsies,
in vitro, or in silico modeling. A deeper understanding of
how these parameters affect outcome can improve trial
design by allowing for rational prognostic strata criteria in
stratified randomization or informing prior probabilities in
a Bayesian clinical trial.34,40,41 Furthermore, Bayesian trial
interim analyses can be enhanced with additional simulations using updated parameters as patient characteristics are
observed or assessed over time. With a better understanding
of the prognostic factors of the population enrolled in a
trial, these interim analyses may be used to update prior
probabilities, predict probability of success, and assess
sample size requirements.40,41
It is important to note that the model demonstrated in
this work is not a perfect representation of tumor growth
and treatment because it fails to consider intratumoral
heterogeneity, metastasis location, and the inherent risks of
treatment. However, because of its simplicity, this model
provides a foundation exploring the current parameter
space while allowing researchers to add complexity as they
see fit.
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There are minimal recently published clinical trial results that support upholding the current paradigm in the
treatment of oligometastases; however, this is likely due in
part to publication bias where positive results are more
likely to be published, not simply because this null hypothesis has always been rejected.17,18 The clinical trials
examined in this article have necessarily sought to examine
the fundamental idea that oligometastatic lesions should
only be targeted for palliative care. Refuting this standard
was crucial, as the earlier state of cancer imaging and
treatment established that targeting oligometastases either
occurred too late or caused too much harm. Yet, as quantitative models of tumor growth and the knowledge of how
metastatic detection and treatment have evolved, we believe
that clinical trials can now provide an even greater benefit
by reconsidering the default null hypothesis and using the
quantitative principles of this mathematical model in trial
design.
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